Encasings for mattresses, blankets and pillows in combination with mite
allergen reduction on the floor have proved effective in reducing
bronchial hyperreactivity of mite-allergic children. We studied the effect of combining the use of encasings with specific
immunotherapy in comparison to the use of encasings alone (control group). Twenty mite-allergic children (Skin Prick Test, RAST, mean age 10 years) with
asthma and high domestic mite
allergen exposure ( > 2 microg
Der p 1 + f 1/g mattress dust) were included in our study. The concentration of these major
allergens as well as specific and nonspecific
bronchial hyperreactivity (PC20 FEV1
histamine) were assessed before, 6 months after and 1 year after start of treatment. All children received elongated polytetrafluorethylene (ePTFE;
Goretex/Intervent
Allergy Bedding System) encasings. A subgroup of eight children were treated additionally by specific
immunotherapy with a partially purified mite extract (ALK Scherax) and a maximum dose of 100000 SQ-U Der p + f. Initially both groups were comparable with respect to the parameters assessed. In 80% of children, encasings reduced
Der p 1 and
Der f 1 concentrations on the mattress to below 3% of the initial values (P < 0.01). The median reduction was 99%. PC20 FEV1
histamine increased from 0.4 to 1.4 mg/dl (median) in the combined group with
immunotherapy and encasings (P < 0.05) and remained essentially unchanged in the control group. PC20 FEV1 Der p did not increase significantly in either group.
CONCLUSION: